Head & Neck Cancer | Topics

First-Line Treatment With TPEx Regimen Did Not Improve OS Compared With EXTREME For HNSCC
April 08, 2021

Docetaxel in combination with cisplatin and cetuximab did not significantly improve overall survival compared with platinum chemotherapy plus fluorouracil and cetuximab but maintained a favorable safety profile.

New Biweekly Dosage of Cetuximab Receives FDA Approval for CRC, HNSCC Subtypes
April 07, 2021

The FDA recently granted approval to a new dosing regimen for cetuximab to treat patients with KRAS wild-type, EGFR-expressing colorectal cancer or head and neck squamous cell carcinoma.

Avelumab Plus Chemotherapy Fails in HNSCC Phase 3 Trial, Raises Future Research Questions
April 02, 2021

Despite the success of immune checkpoint blockade in the treatment of recurrent or metastatic head and neck squamous cell carcinoma, the use of the PD-L1 inhibitor avelumab failed to prolong progression-free survival for patients with locally advanced disease.